Introduction
Transplantation-associated thrombotic microangiopathy (TA-TMA) is an uncommon though typically devastating complication of allogeneic haematopoietic progenitor cell transplantation (SCT). [1] [2] [3] [4] Diagnosis of TA-TMA is based on the presence of thrombocytopenia and microangiopathic haemolytic anaemia (MAHA) in the absence of an alternative clinically apparent aetiology. [2] [3] [4] Similar to idiopathic thrombotic thrombocytopenic purpura (TTP), TA-TMA is also associated with the development of renal dysfunction and neurological complications. [2] [3] [4] However, as both thrombocytopenia and fragmentation of RBC (the hallmark of MAHA) are extremely common post-SCT, and renal dysfunction and neurological complications post-SCT can occur secondary to a diverse range of aetiologies, definitive diagnosis of TA-TMA is often somewhat uncertain. [1] [2] [3] [4] [5] [6] [7] This uncertainty in diagnosis has led to wide variations in the reported incidence of TA-TMA, a lack of consensus regarding clinical approach to management, and poor understanding of prognostic factors with respect to therapeutic response and survival. [1] [2] [3] [4] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] To address this issue of diagnostic clinical uncertainty, two new diagnostic criteria for TA-TMA have recently been proposed; the Bone Marrow Transplant Clinical Trials Network (BMT-CTN) and the IWG (International Working Group) TA-TMA criteria. 24, 25 However, neither criterion has been rigorously evaluated clinically, and issues remain with respect to the diagnostic sensitivity of both. 26 Optimal management of TA-TMA is currently not defined. Owing to its clinical similarities to idiopathic TTP, TA-TMA has traditionally been managed by plasma infusions or therapeutic plasma exchange (PE). However, recent publications have suggested that PE has limited efficacy in treatment of TA-TMA, with relatively low response rates (20-50%) in comparison to idiopathic TTP (75%) generally reported. 2, 3, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] This overall poor response to PE in TA-TMA is not necessarily surprising in light of recent insights into its pathogenesis, which suggest that TA-TMA is, in fact, a multifactorial disorder resulting from endothelial cell dysfunction secondary to a variety of insults, including immunosuppressive medications, GVHD and (especially viral) infection. 2, 3, 8 Unlike idiopathic TTP, TA-TMA has only rarely been associated with severe deficiency of the plasma protease ADAMTS13. 8, [27] [28] [29] Current therapeutic recommendations of TA-TMA revolve around treatment of and/or elimination of conditions resulting in endothelial insult. 2, 3 These recommendations include immediate cessation of potential culprit medications and aggressive treatment of associated GVHD and/or infection. Owing to its relatively poor response rate, PE is generally no longer recommended as standard therapy for TA-TMA. 2, 3, 24 However, this belies the fact that significant clinical responses have been reported in a significant minority of patients treated with PE in a majority of published TA-TMA series to date. [1] [2] [3] [4] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Owing to this historic experience, in many transplant centres, including our own, PE continues to be used in the management of TA-TMA. In an attempt to determine which clinical factors may be predictive of response (or lack thereof) to PE, we retrospectively reviewed the outcomes of TA-TMA treated with therapeutic PE at our institution.
Materials and methods
Patients who had been previously diagnosed with TA-TMA post-allogeneic SCT between December 2001 and March 2008 and treated with therapeutic PE were identified from an institutional database.
Local diagnosis of TA-TMA was previously based on the presence of thrombocytopenia (450% fall in plt count or plt count persistently o20 Â 10 9 per litre) in combination with MAHA in the absence of an alternative clinically apparent aetiology. Local criteria for diagnosis of MAHA included the development of anaemia with fragmented RBC (schistocytes) on peripheral blood smear in combination with a significant elevation (43 Â upper limit of normal) of lactate dehydrogenase (LDH; normal range 110-250 U/l). Note that as the study period pre-empted the development of the recently proposed BMT-CTN and IWG diagnostic criteria, these criteria were not employed prospectively for TA-TMA diagnosis. 24, 25 However, retrospective classification under BMT-CTN criteria is included in Table 2 . Issues with respect to diagnostic sensitivity of the recently proposed BMT-CTN and IWG criteria (including counting of schistocytes) have been recently reviewed. 26 Estimation of percentage of schistocytes on blood films was performed at time of TA-TMA diagnosis by counting 200 red cells under high power magnification. Schistocyte percentage was recorded as a comment on the reporting of peripheral blood smears as per previous recommendations as follows: 9 o1.3% schistocytes 'occasional' fragmentation; 1.3-4.8% schistocytes 'mild' fragmentation; 4.8-9.6% schistocytes 'moderate' fragmentation and 49.6% schistocytes 'severe' fragmentation.
TA-TMA grade and TA-TMA index (LDH/plt count ratio) were calculated as previously published. 9 In short, TA-TMA grade was based on schistocyte percentage and LDH, with o1.3% schistocytes grade 0 (irrespective of LDH level), grade 1 X1.3% schistocytes in combination with normal LDH and grade 2-4 TA-TMA X1.3% schistocytes in combination with (any) elevated LDH (grade 2 schistocytes 1.3-4.8%; grade 3 schistocytes 4.9-9.6% and grade 4 schistocytes X9.7%). TA-TMA index was the ratio of LDH over plt count, with individuals receiving plt transfusions considered to have a plt count of 20 Â 10 9 per litre in determining the ratio. Therapeutic PE was performed on a COBE Spectra (Version 6.0, TPE; Caridian BCT Inc., Lakewood, CO, USA) with 1-1.5 plasma volumes exchanged using cryoprecipitate poor plasma (if available) as replacement, on a daily or alternate daily schedule (depending on availability of apheresis machines) until response, progression or toxicity. Whenever possible, calcinuria inhibitors (CsA or tacrolimus) were ceased at diagnosis of TA-TMA. Refractory acute GVHD was managed with etanercept-based therapy as previously published. 30 Concomitant infections were treated with appropriate antibiotics; if present, CMV reactivation (monitored by weekly quantitative PCR) was treated pre-emptively with i.v. ganciclovir.
Response to PE was determined retrospectively and defined as complete response (CR) if Hb, plt count, LDH, bilirubin and creatinine returned to pre diagnosis levels in combination with complete resolution of any neurological dysfunction present at TA-TMA diagnosis; partial response if plt counts improved to X50% of plt counts pre TA-TMA diagnosis and no response (NR) if o50% or no improvement in plt counts occurred with PE.
Overall survival, specific complications and cause of death were determined retrospectively by review of patient medical records. Overall survival was calculated from day of TA-TMA diagnosis using the Kaplan-Meier method, and survival data were compared using the log-rank test. Categorical data were compared using the two-tailed Fisher's exact test or w 2 -test, where appropriate. Continuous variable data were analysed by the Mann-Whitney test for comparison of tacrolimus levels, the KruskalWallis test for comparison of TA-TMA grade and TA-TMA index and logistic regression analysis for comparison of TA-TMA index and LDH with response to PE.
Results
During the study period, a total of 496 allogeneic SCT had been performed at our institution, with 11 patients diagnosed with TA-TMA treated with PE identified.
Transplant details, individual TA-TMA manifestations, number of exchanges performed, response to PE and patient outcomes for the 11 PE-treated patients are shown in Tables  1 and 2 . All 11 patients met the criteria for multifactorial fulminant TA-TMA under earlier classifications, and 9 patients (82%) retrospectively fulfilled BMT-CTN diagnostic criteria. 4, 24 Of note, the two patients who did not fulfil BMT-CTN diagnostic criteria met the criteria for 'probable' TA-TMA as recently proposed by Cho et al. 31 No correlation was observed between grade of TA-TMA and TA-TMA index (median TA-TMA index 108, 58 and 48.1 for grade 0, 2 and 3 TA-TMA, respectively, P ¼ 0.71).
Overall a median of six exchanges were performed per patient (range 4-13; Table 2 ). Cryoprecipitate poor plasma was used as plasma replacement in all patients except patient number 4, in whom fresh frozen plasma was used. Calcinuria inhibitors were able to be ceased at TA-TMA diagnosis in nine patients (82%). Median trough CsA or tacrolimus levels at diagnosis of TA-TMA were 212 mg/l (range 68-384 mg/l; normal range 120-300 mg/l) and 24 mg/l (range 1.1-36.1 mg/l; normal range 10-30 mg/l), respectively.
Overall response to PE was 27%, with three CRs and eight NRs. There was no difference in the number of exchanges performed in the CR vs NR patients (median 6, range 5-13 vs median 7, range 4-13, respectively; P ¼ 0.57).
However, response to PE was significantly associated with the absence of active acute GVHD at TA-TMA diagnosis, with three CR in the four patients without acute GVHD, and NRs in the seven patients with active acute GVHD (P ¼ 0.024). Interestingly, in two patients with active acute GVHD failing PE, TA-TMA eventually improved (one CR and one partial response) after PE was ceased and GVHD controlled with the introduction of alternative immunosuppressive agents (patients 2 and 3; Table 2 ). There was no significant association seen between response to PE and grade of TA-TMA (P ¼ 0.179), TA-TMA index (P ¼ 0.25) or LDH measurements (P ¼ 0.31).
Trough tacrolimus levels at diagnosis of TA-TMA in the three responding patients were 1.1 mg/l (patient 11), 25.4 mg/l (patient 10) and 36.1 mg/l (patient 1). There was no significant difference between trough tacrolimus levels at TA-TMA diagnosis in responders to PE vs PE non-responders (median tacrolimus level 25.4 mg/l, range 1.1-36.1 vs median 19.4 mg/l, range 12.1-26.2, respectively; P ¼ 0.79).
All 11 patients required insertion of an i.v. apheresis catheter to allow PE to be performed. Catheter-related bacterial sepsis occurred in five patients (45%), and was directly responsible for the death of one (patient 9). Cultured organisms included Enterococcus faecalis (patient 5), Staphylococcus epidermidis (patient 7), Klebsiella pneumonia (patient 8), Acinetobacter calcoaceticus (patient 9) and Bacillus cereus (patient 11). Catheterassociated exit-site infections with S. epidermidis and S. aureus also complicated PE in cases 2 and 8, respectively. Although infectious complications occurred more frequently in patients with active acute GVHD (five of seven patients) in comparison with those without acute GVHD (one of four patients), due to small patient numbers, this association was NS (P ¼ 0.24).
Regular (daily) plt transfusions were required in all patients throughout the duration of PE therapy to maintain plts 410-20 Â 10 9 per litre. Significant bleeding events during PE occurred in three patients (patients 2, 4 and 6); in all cases bleeding episodes occurred in relation to pre-existing conditions (BK-virus haemorrhagic cystitis, diffuse alveolar haemorrhage and gastrointestinal GVHD, respectively). No patient suffered a clinically significant thromboembolic complication.
Median overall survival post-TA-TMA diagnosis was 34 days (range 5-726 days), with only one patient alive on extended follow-up ( Figure 1 and Table 2 ). Although a trend to improved survival was seen in patients responding to PE vs those unresponsive, overall patient numbers were too small to make any definitive conclusions (Figure 1 ; P ¼ 0.136). Causes of death are detailed in Table 2 ; of note, no patient death was directly attributable to TA-TMA per se.
Discussion
Our experience in the use of therapeutic PE for the management of TA-TMA suggests that PE may indeed be effective in the treatment of this disorder, depending on the clinical circumstance in which it develops. Our findings are in concordance with previous publications of use of PE in TA-TMA, in which significant response rates to PE have been reported. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] Of note, all patients in our series had multifactorial fulminant TA-TMA, a subgroup of TA-TMA initially reported to be unresponsive to PE. 4, 10 However, subsequent experience suggested that mild Grades (0-2) of multifactorial fulminant TA-TMA may indeed respond to PE. 11, 12 Alternative predictors of response to PE have been reported by other authors, including TA-TMA index and LDH level. [13] [14] [15] Unlike these reports, we found no association between response to PE and grade of TA-TMA, TA-TMA index or LDH, but instead a significant association between response and presence or absence of active acute GVHD. Interestingly, resolution of TA-TMA in our patients with acute GVHD was seen only after subsequent control of GVHD through the alteration in immunosuppression. Overall, our experience suggests that the use of PE to treat TA-TMA can be pragmatically based on the clinical circumstance in which it develops, with PE potentially efficacious in the absence of active acute GVHD, and essentially ineffective when acute GVHD is manifest. The main complication of PE experienced in our series was line-related infections, which occurred in almost half of the patients and was directly responsible for one patient's death. However, this high infection-related complication rate is not unsurprising given the markedly immunosuppressed state of post-SCT patients, with a majority in our series suffering acute (often refractory) GVHD. Indeed, in a previously published series of refractory GVHD patients treated with etanercept-based therapy at our institution, the overall incidence of bacterial sepsis was 430%. 30 Despite the multiple publications assessing the efficacy of PE as treatment for TA-TMA, almost none detail non-lethal infectious complications occurring during therapy, and as such, the risk of PE-related complications in TA-TMA is typically inferred from data obtained from therapeutic PE in idiopathic TTP. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] 32, 33 Our experience suggests that the risk of catheter-related sepsis in TA-TMA is greater than previously considered, especially in the presence of acute GVHD. In combination with the (absent) response rate to PE in patients with TA-TMA associated with acute GVHD, it seems difficult to justify PE as a routine therapeutic intervention for TA-TMA in this subgroup of patients. As per recent reports, the use of plt transfusions was not associated with precipitation of thromboembolic events. Why should PE be effective in management of TA-TMA, when, unlike idiopathic TTP, TA-TMA has not been associated with autoantibody production and/or severe deficiency of the plasma protease ADAMTS13? 8, [27] [28] [29] Although the exact mechanisms involved in pathogenesis of TA-TMA in different clinical settings post-SCT are not currently known, the development of endothelial cell injury or dysfunction seems to represent a final common pathway in the pathogenesis of MAHA post-SCT. 2, 3 Several drugs used in SCT, and various cytokines associated with GVHD and other post-SCT complications, can potentially induce endothelial cell apoptosis and/or dysfunction, including calcinuria inhibitors, IL-1 and TNFa. 2, 3 One hypothesis is that PE may induce clinical responses by simply reducing plasma concentrations of drugs and/or cytokines driving endothelial cell damage. Further study on mechanisms of response to PE in TA-TMA is needed.
In conclusion, our experience in the use of therapeutic PE for the management of TA-TMA suggests that PE may indeed be effective in the treatment of this disorder, depending on the clinical circumstance in which it develops. PE is potentially efficacious in the absence of active acute GVHD, though both ineffective and associated with high toxicity when acute GVHD is manifest.
